Title :

Role of Allogeneic Transplantation In Chronic Myelomonocytic Leukemia: An International Collaborative Analysis.

Author(s) :

Robin, Marie [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
De Wreede, L. C. [Auteur]
Padron, E. [Auteur]
Bakunina, K. [Auteur]
Fenaux, Pierre [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Koster, L. [Auteur]
Nazha, A. [Auteur]
Beelen, D. W. [Auteur]
Rampal, R. K. [Auteur]
Sockel, K. [Auteur]
Komrokji, R. S. [Auteur]
Gagelmann, N. [Auteur]
Eikema, D. J. [Auteur]
Radujkovic, A. [Auteur]
Finke, J. [Auteur]
Potter, V. [Auteur]
Killick, S. [Auteur]
Legrand-Izadifar, Faezeh [Auteur]
Institut Paoli-Calmettes [IPC]
Solary, Eric [Auteur]
Institut Gustave Roussy [IGR]
Broom, A. [Auteur]
Garcia-Manero, G. [Auteur]
Rizzoli, V. [Auteur]
Hayden, P. [Auteur]
Patnaik, M. M. [Auteur]
Onida, F. [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Itzykson, Raphael A. [Auteur]
Génomes, biologie cellulaire et thérapeutiques [GenCellDis (U944 / UMR7212)]

Journal title :

Blood

Abbreviated title :

Blood

Volume number :

140

Publication date :

2022-06-08

ISSN :

1528-0020

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

To determine the survival benefit of allogeneic hematopoietic cell transplantation (allo-HCT) in chronic myelomonocytic leukemias (CMML), we assembled a retrospective cohort of CMML patients 18-70 years old diagnosed between ...
Show more >To determine the survival benefit of allogeneic hematopoietic cell transplantation (allo-HCT) in chronic myelomonocytic leukemias (CMML), we assembled a retrospective cohort of CMML patients 18-70 years old diagnosed between 2000 and 2014 from an international CMML dataset (n = 730) and the EBMT registry (n = 384). The prognostic impact of allo-HCT was analyzed through univariable and multivariable time-dependent models and with a multistate model, accounting for age, sex, CMML prognostic scoring system (low or intermediate-1 grouped as lower-risk, intermediate-2 or high as higher-risk) at diagnosis, and AML transformation. In univariable analysis, lower-risk CMMLs had a 5-year overall survival (OS) of 20% with allo-HCT vs 42% without allo-HCT (P < .001). In higher-risk patients, 5-year OS was 27% with allo-HCT vs 15% without allo-HCT (P = .13). With multistate models, performing allo-HCT before AML transformation reduced OS in patients with lower-risk CMML, and a survival benefit was predicted for men with higher-risk CMML. In a multivariable analysis of lower-risk patients, performing allo-HCT before transformation to AML significantly increased the risk of death within 2 years of transplantation (hazard ratio [HR], 3.19; P < .001), with no significant change in long-term survival beyond this time point (HR, 0.98; P = .92). In higher-risk patients, allo-HCT significantly increased the risk of death in the first 2 years after transplant (HR 1.46; P = .01) but not beyond (HR, 0.60; P = .09). Performing allo-HCT before AML transformation decreases life expectancy in lower-risk patients but may be considered in higher-risk patients.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-12T01:19:26Z
2024-03-27T14:12:23Z